▲ 2.50%
prev close
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-07-10 | OGNOrganon & Co. | Sell | $1,001 - $15,000 | 129d ago | — |
2025-07-10
Gary Peters
OGN
Amount
$1,001 - $15,000
Filed
129d ago
Recent News
Powered by Polygon.io
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
Vitally Important: National Women’s Health Summit Tickets On Sale Now
Trade Timeline
Congressional activity, newest first
Gary Peters
2025-07-10 · Sale
$1,001 - $15,000